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FOR WORD
The European Science Foundation (ESF) is a major international funding
organisation supporting the collaboration and the meetings of European scientists.
It is based in Strasbourg and it is financed by National Science Foundations of
major West European countries. The programme Chemistry of Metals in Biological
Systems has sponsored the Workshop on "Impact of Metal Ions on Drugs,
Chemotherapeutics and Related Compounds". Almost all the lectures prersented
during this meeting are published in this issue.
The discovery of the anti-tumour activity of platinum complexes promoted
enormous interest in the research on many other inorganic compounds which
might make good new anti-cancer agents. Cisplatinum was not the first metal
complex tried out in cancer therapy. First systematic studies on the structure-activity
relationship of tumour-inhibiting metal compounds and toxicity were started more
than 50 years ago by Collier and Krauss. Platinum complexes, however, were
found to be very efficient and became widely used in the clinic. Platinum
compounds, however, are extremely toxic and in fact, they are really effective in a
very limited number of cancers (testicular carcinoma and a few others). This
promotes a very intensive research in the field. One approach is to improve
properties of the platinum drugs (lower toxicity, higher specificity to cancer cells
and more broad spectrum of cured tumours).
The new developments of platinum anti-cancer drugs, however, may not lead to
new mechanisms of action and new structure-activity relationships, which are
needed when new families of drugs are searched. Thus, inorganic chemists try to
develop both platinum-type drugs as well as new kind of compounds (e.g. Ru or
Sn-based drugs) which may act differently than cisplatin.
The field of inorganic drugs is, of course, not limited only to spectacular
achievements of cisplatin. Gold compounds used for 7000 years in curing of
various diseases, the question of metal ion toxicity (iron overload, heavy metal
toxicity) and chelating agents, the transport of inorganic species through a living
system, the effect of metal ions on existing organic drugs or the use of inorganic
complexes in diagnosis (lanthanides in NMR imaging) are also important elements
of bioinorganic chemistry and pharmacology.
The interdisciplinary character of this field brings together chemists,
pharmacologists, biochemists, physicians, biophysicists. This broad approach to
inorganic drugs gives reasearchers, especially young scientists, a great oportunity
to develop new ideas and to perceive studied objects in a modern and universal
way.
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